SYK and B-cell chronic lymphocytic leukemia: A more targeted approach is illustrated by our studies of the dual PIM and PI3-kinase inhibitor, IBL-202[118], and by studies of the dual SYK/JAK inhibitor cerdulitinib, which is currently in a clinical trial[75]; in vitro studies of both IBL-202 and cerdulitinib[76] demonstrate that these drugs are effective against CLL cells under conditions known to confer resistance to drugs in current clinical use, including ibrutinib and venetoclax.